Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.34 |
| ▸ | SLC2A4 | P14672 | 11/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 4/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454972 | 0.95 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL29454976 | 0.95 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL29454974 | 0.95 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL798149 | 0.95 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL11928145 | 0.94 | SLC2A1 (0.32) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL10083626 | 0.94 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL13085303 | 0.94 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL11928142 | 0.93 | SLC2A1 (0.33) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL15963579 | 0.91 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL798276 | 0.90 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056861-B2 | Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorphs of these derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-8969572-B2 | Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorphs of these derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20150025116-A1 | PROCESS FOR PREPARING TETRAZOLE-SUBSTITUTED ANTHRANILAMIDE DERIVATIVES AND NOVEL CRYSTAL POLYMORPHS OF THESE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20120101133-A1 | PROCESS FOR PREPARING TETRAZOLE-SUBSTITUTED ANTHRANILAMIDE DERIVATIVES AND NOVEL CRYSTAL POLYMORPHS OF THESE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025116-A1 | PROCESS FOR PREPARING TETRAZOLE-SUBSTITUTED ANTHRANILAMIDE DERIVATIVES AND NOVEL CRYSTAL POLYMORPHS OF THESE DERIVATIVES | CYP4F3, CYP4F12, CYP3A5 | SLC2A1 4160/4885SLC2A3 3615/4885SLC2A4 3964/4885 |
| US-20120101133-A1 | PROCESS FOR PREPARING TETRAZOLE-SUBSTITUTED ANTHRANILAMIDE DERIVATIVES AND NOVEL CRYSTAL POLYMORPHS OF THESE DERIVATIVES | CYP4F3, CYP4F12, CYP3A5 | SLC2A1 4160/4885SLC2A3 3615/4885SLC2A4 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.